Related Experiment Video

Updated: Mar 14, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

21.4K

Optimizing antifungal strategies to improve patient survival

Paul Verweij1, Sue Lyon2

  • 1Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.

Future Microbiology
|October 4, 2016
PubMed

Insights

Invasive fungal infections pose a significant risk to immunocompromised patients, particularly those with neutropenia. Antifungal drug resistance and high mortality rates remain critical concerns in managing these infections.

Area of Science:

  • Clinical Microbiology
  • Infectious Diseases
  • Mycology

Background:

  • Invasive fungal infections (IFIs) are a major cause of mortality in immunocompromised patients.
  • Neutropenic hemato-oncology patients face a particularly high risk of IFIs.
  • Effective antifungal treatment and prophylaxis are crucial for improving survival rates.

Purpose of the Study:

  • To highlight key discussions on invasive fungal infections from the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016).
  • To address the growing concern of antifungal drug resistance in managing IFIs.
  • To emphasize the persistent high mortality associated with IFIs despite appropriate treatment.

Main Methods:

  • The content is based on discussions and presentations at the 26th ECCMID congress.
  • Expert insights from over 11,600 clinical microbiologists and infectious disease physicians were shared.
  • Topics covered included antifungal resistance, treatment strategies, and patient outcomes.

Main Results:

  • Antifungal drug resistance is an increasing concern, complicating treatment efficacy.
  • Mortality rates for IFIs remain high, even with timely and appropriate antifungal therapy.
  • The congress provided a platform for addressing these critical challenges in infectious disease management.

Conclusions:

  • Managing invasive fungal infections in immunocompromised patients requires ongoing attention to treatment strategies and resistance patterns.
  • Further research and collaboration are essential to combat antifungal resistance and reduce IFI-related mortality.
  • ECCMID 2016 underscored the importance of addressing these challenges in clinical microbiology and infectious diseases.
Keywords:
·antifungal drug resistanceantifungal prophylaxisantifungal stewardshipantifungal therapyinvasive fungal infections

More Related Videos

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

7.5K
Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

14.3K

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.7K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
811
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63